WHO Unveils Strategic R&D Blueprints to Pre-empt Future Pandemics
In a major push to strengthen global health security, the World Health Organization (WHO) and its partners announced a new set of research and development (R&D) blueprints targeting ten priority virus and bacteria families on April 7, 2026. The initiative, unveiled during the “One Health Summit” in Lyon, France, aims to ensure that the international community has safe and effective vaccines, diagnostic tools, and treatments ready before the next global health crisis strikes.
The strategy is designed to reduce the uncertainty and chaos often associated with early-stage outbreaks by establishing a coordinated, global framework for preparation. The project was co-hosted by the Coalition for Epidemic Preparedness Innovations (CEPI) and the French National Agency for AIDS and Emerging Infectious Diseases (ANRS MIE).
Central to this effort is the establishment of Collaborative Open Research Consortia (CORCs). These consortia function as a global network of research institutions focusing on core bacterial threats and priority virus families. According to WHO Chief Scientist Dr. Sylvie Briand, the CORC mechanism is shifting global scientific collaboration toward a framework that is more “permanent, decentralized, and inclusive.”
Each CORC is managed by a leading agency and utilizes structured, open scientific consultations to build its specific R&D blueprint. These consultations are comprehensive, covering critical areas such as:
- Pathogen biology and the study of animal hosts and vectors.
- Epidemiological surveillance and monitoring.
- Basic and translational research.
- The development and regulatory requirements for medical countermeasures.
- Evaluation protocols for candidate medical countermeasures during active outbreak scenarios.
This “pathogen family-oriented” strategy is a response to the unpredictable nature of emerging infectious diseases. Dr. Richard Hatchett, CEO of CEPI, noted that given that the timing and identity of the next pandemic threat are unknown, focusing on entire families of pathogens allows the global community to stay ahead of both known risks and entirely new threats.
This approach supports CEPI’s “100-Day Mission,” an ambitious goal to develop safe, effective, and accessible vaccines within 100 days of identifying a new threat. These efforts are part of the broader CEPI 3.0 strategy spanning 2027 to 2031.
The urgency of these blueprints is underscored by the concept of “Disease X”—a placeholder name adopted by the WHO in 2018 for a currently unknown pathogen that could cause a future pandemic. Whether arising from zoonotic transmission or biological weapons, Disease X represents the high-risk, low-preparedness gap that these new blueprints aim to close.
However, technical readiness is only one part of the challenge. Although the R&D blueprints provide a scientific roadmap, political hurdles regarding equity remain. Negotiations for the “Pathogen Access and Benefit-Sharing” (PABS) system—a critical component of the Pandemic Agreement—have faced delays. Member states have struggled to reach a consensus on how to share pathogen data in exchange for equitable access to the resulting medical products.
While many nations, particularly in Africa, insist that sharing data must guarantee access to the resulting treatments and vaccines, several European nations with large pharmaceutical industries have warned that mandatory sharing could stifle innovation. Following a lack of consensus in late March, the WHO announced that new rounds of negotiations for the PABS system will take place from April 27 to May 1, 2026, ahead of the World Health Assembly in mid-May.
By integrating the “One Health” approach—which recognizes the interconnection between people, animals, and their shared environment—these R&D blueprints represent a critical shift from reactive crisis management to a proactive defense system for global public health.
WHO promotes pathogen R&D blueprints to strengthen global pandemic prevention capabilities
